Table 1.
Baseline characteristics of patients with documented remission after first-line induction therapy.
| LEAD Cohort Relapse (n = 53) | MER Cohort Relapse (n = 113) | Combined Relapse (n=166) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No Relapse Detected (LEAD) | Relapse Detected (LEAD + MER) | Total LEAD | Clinical Relapse Detection | Radiographic Relapse Detection | P | Total MER | Clinical Relapse Detection | Radiographic Relapse Detection | P | Total Combined | Clinical Relapse Detection | Radiographic Relapse Detection | P | |
| Total | n = 93 (36.4%) | n = 172 (63.6%) | 148 | 11 = 35 (66%) | n = 18 (34%) | 117 | n = 63 (53.8%) | n = 50 (42.7%) | 265 | n = 98 (59.04%) | n = 68 (40.96%) | |||
| Age#, years | 59.01 [31.50, 83.84] | 58.00 [22.25, 83.84] | 57.54 [22.25, 83.84] | 52.46 [45.42, 64.65] | 60.73 [48.7, 63.46] | 0.453** | 59.00 [35.32, 83.25] | 59 [49, 66] | 60.09 [49, 69.04] | 0.619** | 59.00 [22.25, 83.84] | 57.21 [48, 65] | 60.42 [49, 67.38] | 0.317** |
|
Gender
Male Female |
40 (43%) 53 (57.0%) |
97 (56.4%) 75 (43.6%) |
66 (44.59%) 82 (55.41%) |
14 (40%) 21 (60%) |
10 (55.56%) 8 (44.44%) |
0.281* |
71 (60.70%) 46 (39.30%) |
43 (68.25%) 20 (31.75%) |
26 (52%) 24 (48%) |
0.078* |
137 (51.70%) 128 (48.30%) |
41 (41.84%) 57 (58.16%) |
32 (47.06%) 36 (52.94%) |
0.505* |
|
Ethnicity
White Other |
65 (69.9%) 28 (30.1%) |
150 (88.2%) 20 (11.8%) |
104 (70.27%) 42 (29.73%) |
24 (68.57%) 11 (31.43%) |
14 (77.78%) 4 (22.22%) |
0.539** |
111 (96.50%) 4 (3.50%) |
61 (98.93%) 1 (1.61%) |
47 (94%) 3 (6%) |
0.323** |
215 (81.70%) 48 (18.30%) |
85 (86.73%) 12 (12.24%) |
61 (89.71%) 7 (10.29%) |
0.681* |
|
Stage
1,2 3,4 |
27 (29.3%) 65 (70.7%) |
27 (16.0%) 142 (84.0%) |
36 (25.00%) 108 (75.00%) |
7 (21.88%) 25 (78.13%) |
2 (11.11%) 16 (88.89%) |
0.459** |
18 (15.4%) 99 (84.60%) |
8 (12.7%) 55 (87.3%) |
9 (18%) 41 (82%) |
0.434* |
54 (20.70%) 207 (79.3%) |
15 (15.79%) 80 (84.21%) |
11 (16.18%) 57 (83.82%) |
0.947* |
|
Grade
1,2 3 |
75 (83.3%) 15 (16.7%) |
145 (84.8%) 26 (15.2%) |
119 (82.60%) 25 (17.4%) |
29 (82.86%) 6 (17.14%) |
14 (82.35%) 3 (17.65%) |
1.000** |
101 (86.30%) 16 (13.7%) |
54 (85.71%) 9 (14.29%) |
43 (86%) 7 (14%) |
0.965* |
220 (84.3%) 41 (15.7%) |
83 (84.69%) 15 (15.31%) |
57 (85.07%) 10 (14.93%) |
0.947* |
|
ECOG
0 ≥1 |
43 (47.8%) 47 (52.2%) |
91 (54.4%) 72 (45.2%) |
58 (41.40%) 82 (58.60%) |
8 (25%) 24 (75%) |
7 (43.75%) 9 (56.25%) |
0.186* |
76 (65.50%) 40 (34.5%) |
36 (58.06%) 26 (41.94%) |
36 (72%) 14 (28%) |
0.126* |
134 (52.30%) 122 (47.70%) |
44 (46.81%) 50 (53.19%) |
43 (65.15%) 23 (34.85%) |
0.022 * |
|
FLIPI
Low Intermediate High |
24 (27.9%) 27 (31.4%) 35 (40.7%) |
36 (22.8%) 53 (33.5%) 69 (43.7%) |
31 (24.40%) 40 (31.50%) 56 (44.10%) |
6 (25%) 6 (25%) 12 (50%) |
1 (6.67%) 6 (40%) 8 (53.33%) |
0.018 ** |
29 (24.80%) 40 (34.20%) 48 841.00%) |
15 (23.81%) 24 (38.1%) 24 (38.1%) |
12 (24%) 16 (32%) 22 (44%) |
0.767* |
60 (24.60%) 80 (32.8%) 104 (42.6%) |
21 (24.14%) 30 (34.48%) 36 (41.38%) |
13 (20.00%) 22 (33.85%) 30 (46.15%) |
0.785* |
|
B-Symp.
Yes No |
13 (15.3%) 72 (84.7%) |
31 (18.8%) 134 (81.2%) |
27 (20.00%) 108 (80.00%) |
13 (40.63%) 19 (59.38%) |
1 (5.88%) 16 (94.12%) |
0.453** |
17 (14.80%) 98 (85.20%) |
10 (16.39%) 51 (83.61%) |
7 (14%) 43 (86%) |
0.728* |
44 (17.60%) 206 (82.4%) |
23 (24.73%) 70 (75.27%) |
8 (11.94%) 59 (88.06%) |
0.043 * |
Clinical detection, defined by patient-reported symptoms at the time of confirmed detection of disease, concerning physical exam findings documented during a clinical visit, or abnormal lab values on prior follow-up; surveillance detection, defined by relapse of disease first suggested on imaging reviewed by a radiologist, as part of a routine surveillance schedule, and later confirmed by other diagnostic means; Variables are presented as N (%) unless otherwise noted; p <0.05 are marked in bold.
Abbreviations: Stage, Ann Arbor Staging; ECOG, Eastern Cooperative Oncology Group performance score; FLIPI, follicular lymphoma international prognostic index risk category; B-symp., B-symptoms present on presentation; Bone marrow involved, involvement of bone marrow by follicular lymphoma on presentation; GELF, Groupe d’Etude des Lymphomes Folliculaires score ≥1.
Variables presented as median [range].
Parametric
Non-parametric p-value